ACHIEVING OPTIMAL OUTCOMES IN Ph+ CML
Today, the goals of treatment for patients with Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia in the chronic phase (CML-CP) have evolved—clinical evidence confirms that faster and deeper reductions of Ph+ CML disease burden, such as major molecular response (MMR) or better, can significantly improve long-term outcomes for patients.1,2,3,4
The information below and accompanying links will help you and your patients to achieve today's optimal treatment goals.
Prescribing GLIVEC (imatinib)
Click Prescribing GLIVEC to view recommended dosing and administration instructions and to learn about the management of potential adverse reactions when treating patients with Ph+ CML.
Click Ongoing Management to read expert recommendations about monitoring patients with Ph+ CML-CP for optimal responses.
Learn about TASIGNA® (nilotinib) for patients who develop resistance or intolerance to GLIVEC
To find out more, click on www.tasigna.com.
- Baccarani M, Cortes J, Pane F, et al; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009;27(35):6041-6051.
- Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon and STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase treated with imatinib. Poster presented at: 51st American Society of Hematology (ASH) Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA.
- Iacobucci I, Saglio G, Rosti G, et al; for the GIMEMA Working Party on Chronic Myeloid Leukemia. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res. 2006;12(10):3037-3042.
- Saglio G, Kim D-W, Issaragrisil S, et al; for ENESTnd investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362(24):2251-2259.
- Marin D, Bazeos A, Mahon F-X, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieved complete cytogenetic responses on imatinib. J Clin Oncol. 2010;28(14):2381-2388.
- Noens L, van Lierde M-A, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401-5411.
- The NCCN Chronic Myelogenous Leukemia Clinical Practice Guidelines in Oncology (Version 1.2011). © 2010 National Comprehensive Cancer Network, Inc. http://www.nccn.org. Accessed August 30, 2010. To view the most recent and complete version of the guidelines, go online to www.nccn.org.
- Druker BJ. Perspectives on the development of a molecularly targeted agent. Cancer Cell. 2002;1(1):31-36.
- Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta. 2005;1754(1-2):3-13.
- TASIGNA® (nilotinib) summary of product characteristics. Basel, Switzerland: Novartis Pharma AG; 2013.
How are the goals
of therapy in Ph+
Are your patients at
risk for progression?
Click here to view
patient case studies